Skip to main content

Table 3 Secondary outcomes at final follow-up

From: Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction

Outcome

Number of event (%)

Statin vs. non-statin

Statin (n = 441)

Non-statin (n = 441)

HR (95% CI)

P value

All-cause mortality

250 (56.7)

271 (61.5)

.70 (.59, .84)

<.001

Hemorrhage stroke

4 (.9)

2 (.5)

1.23 (.22, 6.84)

.810

Heart failure

59 (13.4)

44 (10.0)

1.08 (.73, 1.60)

.714

Acute hepatitis

1 (.2)

3 (.7)

.22 (.02, 2.16)

.194

Rhabdomyolysis

4 (.9)

1 (.2)

3.36 (.38, 30.06)

.279

Newly diagnosed dementia

0 (.0)

1 (.2)

NA

NA

Newly diagnosed malignancy

14 (3.2)

9 (2.0)

1.09 (.46, 2.56)

.844

  1. CI confidence interval, HR hazard ratio, NA not applicable